Unintended pregnancy after gonadal failure chemoprevention with gonadotropin-releasing hormone agonist in women with hematologic malignancies

Fertil Steril. 2009 Oct;92(4):1260-1263. doi: 10.1016/j.fertnstert.2009.02.009. Epub 2009 Sep 3.

Abstract

Many patients who receive co-treatment with GnRH agonists (GnRH-a) during chemotherapy treatment preserve their ovarian function and are at risk of unintended pregnancies. Therefore, it is important to offer them effective contraception. Also, pregnancies occurring after cancer therapy in women who received GnRH-a are not associated with adverse neonatal outcomes.

Publication types

  • Evaluation Study

MeSH terms

  • Adolescent
  • Adult
  • Antineoplastic Agents, Hormonal / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bleomycin / therapeutic use
  • Case-Control Studies
  • Dacarbazine / therapeutic use
  • Doxorubicin / therapeutic use
  • Female
  • Gonadotropin-Releasing Hormone / agonists*
  • Hematologic Neoplasms / complications
  • Hematologic Neoplasms / drug therapy*
  • Hematologic Neoplasms / epidemiology
  • Humans
  • Infant, Newborn
  • Middle Aged
  • Pregnancy
  • Pregnancy Complications, Neoplastic / epidemiology
  • Pregnancy Outcome
  • Pregnancy, Unplanned*
  • Primary Ovarian Insufficiency / prevention & control*
  • Time Factors
  • Triptorelin Pamoate / therapeutic use*
  • Vinblastine / therapeutic use
  • Young Adult

Substances

  • Antineoplastic Agents, Hormonal
  • Triptorelin Pamoate
  • Bleomycin
  • Gonadotropin-Releasing Hormone
  • Vinblastine
  • Dacarbazine
  • Doxorubicin

Supplementary concepts

  • ABVD protocol